Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13448691 | 0.89 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL13392940 | 0.89 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL18638816 | 0.87 | CNR2 (0.39) | CNR2CNR1KCNH2 | |
| SCHEMBL13393274 | 0.86 | — | — | |
| SCHEMBL12824347 | 0.84 | CNR2 (0.32) | CNR2CNR1 | |
| SCHEMBL469435 | 0.84 | CNR2 (0.38) | CNR2CNR1 | |
| SCHEMBL10147821 | 0.82 | CNR2 (0.40) | CNR2CNR1KCNH2 | |
| SCHEMBL10146087 | 0.79 | CNR2 (0.39) | CNR2CNR1KCNH2 | |
| SCHEMBL12289489 | 0.77 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL13392942 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316173-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| WO-2012012307-A9 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012012307-A1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316173-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885KCNH2 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.